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Burkitt lymphoma (BL) is a biologically and molecularly defined tumor hallmarked by IG-mediated 
t(8q24) resulting in upregulation of MYC.1,2 Recent studies of 59 molecular BL (mBL) identified a novel 
aberration manifested by a specific 11q-gain/loss pattern in two cases (3%) lacking MYC translocation.3 
The aberration was subsequently detected in 15 MYC-negative high-grade B-cell lymphomas resembling 
BL and two cell lines derived from high-grade B-cell lymphomas. Further studies defined the minimal 
gained and lost regions at 11q23.3 and 11q24.1qter, respectively, and identified candidate genes 
potentially affected by these imbalances: the constantly overexpressed PAFAH1B2/11q23.3, and FLI1 
(downregulated) and ETS1 (recurrently mutated) targeted by a homozygous 11q24 microdeletion.  
We provide here evidence that this peculiar 11q-gain/loss aberration is particularly frequent in BL in 
immunodeficient hosts, as it was identified in three out of seven patients with mBL after solid organ 
transplantation and under immunosuppressive maintenance. The cases were selected from a cohort of 
174 posttransplant patients diagnosed with posttransplant lymphoproliferative disorders (PTLD) between 
1989 and 2012 at the University Hospitals of KU Leuven (Leuven, Belgium). This cohort mainly  
comprised diffuse large B-cell lymphoma (75%).4,5 Other entities were less frequent and included  
plasmacytoma and plasmablastic non-Hodgkin lymphoma (NHL),6 T-cell NHL,7 BL, small cell B-NHL and 
unspecified cases. The seven posttransplant BL (PT-BL) cases reported here were analysed using 
conventional cytogenetics, array CGH (aCGH), FISH, immunohistochemistry (IHC), gene expression 
profiling (GEP) and bioinformatics (Supplementary information).  As controls, we included four cases of 
typical MYC-translocation-positive BL from immunocompetent hosts (IC-BL). All cases fulfilled the 
morphological and immunological criteria of BL defined by the 2008 WHO classification8 (Table 1).  
Relevant clinical, pathologic and cytogenetic features of the studied cases are summarized in Table 2. 
The PT-BL patients, all men, had undergone liver (n=3), heart (n=2) or kidney (n=2) transplantation. The 
median age at time of PTLD was 47.5 years (range, 15-70 years). Five cases were EBV-negative and two 
adolescent cases (no. 3 and 4) were EBV-positive. Patients developed BL after a median interval of 40.7 
months (range, 11-66 months) following transplantation. The interval was significantly shorter for EBV-
positive cases than EBV-negative cases (12 vs 52.2 months, respectively). All seven patients were treated 
with either rituximab and/or CHOP. Most of them achieved complete remission but four patients died 
within 4-11 months after diagnosis (average 6 months), including two patients (no. 6 and 7) who died due 
to disease-related complications. Three patients are alive, including both EBV-positive patients, and their 
survival ranges from 34 to 99 months (median 70 months) (Table 2). Based on a global gene expression 
pattern, all seven PT-BL cases (as well as control IC-BL cases) showed molecular profile of BL and were 
readily distinguished from PT-/IC-DLBCL5 using two mBL classifiers1,2 (Supplementary Figure 1). 
Cytogenetics and/or FISH demonstrated t(8q24/MYC) in four PT-mBLs, while three cases (no. 5-7, all 
EBV-negative) appeared to be MYC-translocation-negative. Interestingly, karyotypes of the two latter 
cases revealed various 11q aberrations, which after additional FISH analysis (data not shown) were 
described as der(11)(11pter->11q23.3::11q23.3->11q13::8q22q24.3) and der(11)t(11;18)(q23.3;q12) 
(Figure 1A). Array CGH analysis performed in all 11 cases detected the characteristic 11q-gain/loss 
pattern in the three MYC-translocation-negative cases (Figure 1B). This pattern was associated  with a 
dup(11)(q13q23.3) in case 5,  focal gain-and-amplification of ~4Mb region at 11q23.3 in case 6 (confirmed 
by FISH, Figure 1C, Supplementary Figure 2) and complex 11q imbalances in case 7 (Table 2). 
Interestingly,  dup(11)(q13q23.3) identified in case 5 was associated with an inversion, like in several 
previously reported cases.3,9 Losses, resulting from different nonreciprocal translocations in cases 5 and 
6,  constantly targeted the 11q23.3/q24.1qter region.  Homozygous deletions were not detected. The 
aCGH data allowed to define the minimal gained region (MGR) (~4Mb) and minimal lost region (MLR) 
(~13.5Mb) which were mapped at 11q23.3 (chr11:116072765-120087526bp (hg19)) and 11q24.1q25 
(chr11:121499571-135006516bp (hg19)), respectively. Notably, MYC-translocation-positive PT-mBL 
cases had either a balanced karyotype, or were featured by 2-9 additional imbalances, including subclonal 
gains/losses, similar like IC-mBL cases (Table 2). The latter ones, however, showed a frequent gain of 
chromosome 7 (60%), not seen in PT-mBL cases.  
In order to identify genes affected by the 11q imbalances, we compared GEPs of cases 5-7 (11q-
gain/loss-positive) and cases 1-4 (MYC-translocation-positive), and focused on genes harboured by MGR 
(69 genes) and MLR (106 genes). Altogether, 33 genes with a differential expression were identified: 15 at 
MGR (all upregulated) and 18 at MLR (all downregulated) (Supplementary Table 1). The most significantly 
upregulated was USP2 (ubiquitin specific peptidase 2) showing up to 30.6-fold higher expression in MYC-
translocation-negative cases than in MYC-translocation-positive cases (Supplementary Figure 3). 
Differential expression of the remaining MGR genes was much lower (1.35-2.75-fold). Level of 
differentially downregulated genes ranged from -1.32 to -2.35-fold. Notably, both regions harbor several 
genes which might be implicated in the pathogenesis of MYC-translocation-negative mBL. Particularly 
interesting are two oncogenes, USP2 and CBL, and the previously discussed PAFAH1B2 located in 
MGR.3 USP2, which was the most significantly upregulated in 11q-gain/loss-positive mBLs, acts as a 
modulator of TNFα-induced NF-kB signaling and prolongs the half-life of targets such as fatty acid 
synthase, MDM2 and MDM4/MDMX (negative regulators of p53) and cyclin D1 (G1/S transition).  The 
enzyme, like other deubiquitinases, in implicated in cancer, particularly in prostate carcinomas (reviewed 
by Fraile et al.10). In MLR, dysregulated genes comprise two candidate tumor suppressor genes, TBRG1  
and EI24, and five genes either related to cancer or involved in cancer-related processes, including ETS1, 
TIRAP, ST14, NCAPD3  and ZNF202. Noteworthy, FLI1, the candidate target gene,3 was not differentially 
downregulated in our cases (Supplementary Figure 3). Hierarchical clustering of the studied cases using 
the set of 11q23/q24 dysregulated genes showed that MYC-translocation-negative PT-mBL cases cluster 
together and separate from MYC-translocation-positive PT-/IC-mBL (Figure 1D).  
PT-mBL cases with the 11q-gain/loss pattern revealed a lower expression of MYC mRNA than MYC-
translocation-positive cases (Supplementary Figure 3). Using IHC with MYC antibody (clone Y69; 
Epitomics, Burlingame, CA), all studied mBL cases showed highly variable expression of  MYC protein, 
which has not necessarily correlated with rearrangement of MYC  (Table 1) (Supplementary Figure 4). 
These results, however, remain in line with the recently published data of Chisholm et al.11  
To examine whether the 11q-gain/loss aberration also features BL and/or DLBCL cases from 
immunocompetent patients collected in our institution, we analyzed by FISH two known cases of MYC-
translocation-negative BL and five cases of MYC-translocation-negative DLBCL harbouring 11q 
aberrations (mostly dup(11q)). Using the designed 11q23/q24 assay covering MGR and MLR 
(Supplementary Figure 2), the 11q-gain/loss pattern was detected in one of two MYC-translocation-
negative BL case (data not shown). The second BL case showed a normal FISH pattern, while all five 
DLBCLs revealed gain of 11q23.3, without, however, an associated loss of 11q24. These findings confirm  
a rare occurrence of the 11q-gain/loss pattern in IC-BL/-DLBCL.   
To unravel biological consequences of the 11q-gain/loss aberration in mBL, we explored the 
MGR/MLR-dysregulated genes using Ingenuity Pathway Analysis (IPA) (see Supplementary Methods). 
IPA showed that the genes are implicated in important biological processes, including cancer, and the 
majority of them (22/33) are involved in the TP53 and MYC networks, frequently by direct protein-protein 
interactions (Figure 1E). These findings and the observation that cases with 11q imbalances cluster with 
MYC-translocation-positive mBL (using two mBL classifiers1,2) suggest that the 11q-gain/loss aberration is 
a ‘molecular variant’ of t(8q24/MYC) affecting the same or overlapping pathological pathways. Similar 
phenomenon has been recently described in BCR-ABL-negative Ph-like ALL showing a spectrum of 
kinase-activating alterations.12 The astonishing consistency of the 11q-gain/loss pattern suggests that the 
driving potential of this aberration results from a concerted overexpression of the defined 11q23.3 genes, 
including USP2, CBL and PAFAH1B2, and simultaneous downregulation of 11q24q25 genes, among 
others TBRG1, EI24 and ETS1. Interestingly, a similar gain-and-loss pattern has been identified in 
hepatosplenic T-cell lymphoma characterized by a constant 7p14.1p22.1-loss/7q22.11q31.1-gain 
pattern13, which, noteworthy, is frequently observed in immunosuppressed patients.  
PTLD is typically an EBV driven process and our recent study of 33 PT-DLBCL (72% EBV-positive  
and 28% EBV-negative) led to conclusion that EBV-negative PT-DLBCL were coincidental lymphomas in 
immunosuppressed  patients.5  Among the reported PT-mBLs, only 30% of cases were EBV-positive and 
they clustered together with EBV-negative PT-mBL and IC-mBL (Supplementary Figure 1). These findings 
are in line with observations of Piccaluga et al.,14 who found that all three BL subtypes, sporadic, endemic 
and HIV-positive, share a common gene expression signature, distinct from other B-cell malignancies, and 
suggested that not EBV, but MYC-dependent signature had a major effect on the clustering.  
    Altogether, we confirmed a recurrent occurrence of the 11q-gain/loss pattern in high grade  B-cell 
lymphoma and showed that this aberration is significantly more frequent (p-value <0.007, Fisher’s exact 
test) in BL occurring in the setting of transplantation and immunosuppression (43% of all PT-mBL and 
60% of EBV-negative PT-mBL) than in immunocompetent patients (3%)1, suggesting that 
immunosuppression may favour its formation. Further studies of  PT-BL are needed to confirm this 
association.  As identification of patients with the 11q-gain/loss  aberration is clinically important but 
cytogenetically challenging, we recommend the designed 11q-MGR/MLR FISH assay as a useful 
diagnostic tool to evaluate both, posttransplant- and immunocompetent BL patients.  
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Table 1. Morphology and immunophenotype of the reported postransplant and immunocompromised BL cases. 
Case Localization Morphology Immunohistochemistry EBV 
latency 
profile 
CD20 CD10 MYC 
(%) 
TdT BCL2 BCL6 MUM1 Ki67 
(%) 
EBER 
MYC-translocation-positive PT-mBL 
1 LN medium and large-sized cells, limited starry sky pos pos 0  posa pos neg 100 neg   
2 LN large-sized cells, starry sky pos pos 35 neg neg pos neg 100 neg   
3 GALT medium-sized cells, starry sky pos pos 100  neg pos neg 95 pos intermediate 
4 LN medium-sized cells, starry sky pos pos 100 neg neg pos neg 95 pos intermediate 
MYC-translocation-negative PT-mBL 
5 WR large-sized cells, starry sky pos pos 0 neg neg pos neg 90 neg   
6 LN medium-sized cells, starry sky pos pos 25 (w) neg neg pos neg 99 neg   
7 T large-sized cells, starry sky pos pos 75 (w)  neg pos neg 99 neg   
MYC-translocation-positive IC-mBL 
8 GALT large-sized cells, starry sky pos pos 50 neg neg pos pos 100 neg   
9 LN medium-sized cells, starry sky pos pos 90 neg neg pos pos 100 neg   
10 LN medium-sized cells, limited starry sky pos pos 0 neg neg pos neg 90 neg   
11 LN medium-sized cells, starry sky pos pos 25 neg neg pos neg 95 neg   
a normal FISH BCL2 pattern 
PT, posttransplant; IC, immunocompetent; mBL, molecular Burkitt lymphoma; LN, lymph node; GALT, gut associated lymphoid tissue; WR, 
Waldeyer ring; T, testis; pos, positive; neg, negative; w, weak 
  
Table 2. Relevant clinical, pathologic and genetic data of the reported posttransplant and immunocompetent BL cases. 
Case  Age/ Immune 
status 
Graft Immuno-
suppression 
TX-PTDL 
interval 
(months) 
Stage EBV Treatment Response Outcome 
(months) 
Cytogenetic and FISH findings aCGH imbalances (>4Mb) a 
Sex Gains Losses 
MYC-translocation-positive PT-mBL 
1 65/M ID heart CNI+AM 61 IIIA - R CR D/du (11) 47-48,XY,dup(1)(q21q32)[8],t(8;14) 
(q24;q32),+12[3],del(13)(q14q22)[cp20]. nuc 
ish(MYCx2)(5'MYC sep 3'MYCx1)[150/200] 
1p11.2q32.1 13q14.13q31.1 
2 70/M ID liver CNI 31 IVA - CHOP/ 
R 
CR D/dr (4) 46,XY,del(6)(q23),t(8;22)(q24;q11), 
inc[15].nuc ish(MYCx2)(5'MYC sep 
3'MYCx1)[33/200] 
NF NF 
    
3 16/M ID kidney CNI+AM+CS 13 IVA + CHOP/ 
R 
CR A (34) NM.nuc ish(MYCx2)(5'MYC sep 3'MYCx1) 
[160/200] 
1q21.2q25.3; 
3q27.2q29; 
12p13.33p11.22; 
12q14.1q24.21; 
13q31.1q31.3; 
15q24.3q26.2 
16p13.3p13.3 
4 15/M ID liver CNI+AM+CS 11 IIIA + Intensive 
CT 
CR A (79) NM.nuc ish(MYCx2)(5'MYC sep 
3'MYCx1)[190/200] 
no no 
MYC-translocation-negative PT-mBL 
5 54/M ID heart CNI+AM 66 IIA - CHOP/ 
R 
CR A (99) 44-47,XY,add(7)(p22)[3],der(11)(11pter-
>11q23.3::11q23.3->11q13::8q22q24.3),+1-
2mar[cp5].nuc ish(MYCx2)[200] 
8q22.3q24.23; 
11q13.1q23.3; 
12p13.32q13.13 
8p23.3p23.2; 
8q12.1q13.1; 
11q23.3q25; 
20q11.23q13.13; 
21q21.1q21.2 
6 68/M ID liver CNI 46 IA - CHOP/ 
R 
PD D/dr (4) 42-44,XY,-4,add(10)(p11), 
der(11)t(11;18)(q23.3;q12)[cp4].nuc 
ish(MYCx2)[200] 
11q23.3q23.3; 
16q21.1q24.3; 
18q12.1q23 
4p16.3q35.2; 
10p15.3p11.4; 
11q23.3q25; 
20q11.23q13.33 
7 44/M ID kidney CNI+AM 57 IVB - CHOP/ 
R 
CR D/dr (5) ND.nuc ish(MYCx2)[200] 2q23.3q37.3; 
7q32.3q36.3; 
11p15.4p15.1; 
11q13.4q14.1; 
11q22.3q24.1; 
12p13.33q24.33; 
13q32.1q34; 
17q22q23.2 
11q14.1q22.3; 
11q24.1q25; 
13q31.1q32.1;  
MYC-translocation-positive IC-mBL 
8 77/M IC - - - IA - CHOP CR D/du 
(105) 
ND.nuc ish(MYCx2)(5'MYC sep 3'MYCx1) 
[55/100] 
3p26.3q12.2; 
3q26.33q27; 
18q12.1q23 
3q13.11q26.32; 
20q11.23q13.12 
9 36/M IC - - - IIIB -  Intensive 
CT 
CR A (98) ND.nuc ish(MYCx2)(5'MYC sep 3'MYCx1) 
[80/100] 
no no 
10 18/M IC - - - IVB -  CHOP/ 
R 
CR A (106) ND. nuc ish(MYCx2)(5'MYC sep 
3'MYCx1)[62/100] 
7p22.3q36.3; 
12p13.33q24.33; 
21q11.2q22.3 
1p36.33p36.23; 
2q21.2q24.1; 
4q21.1q21.23 
11 75/M IC - - - IVB - CHOP/ 
R 
CR A (45) ND.nuc ish(MYCx2)(5'MYC sep 3'MYCx1) 
[65/100] 
7p22.3q36.3; 
8q22.3q24.3; 
9q21.11q34.3 
5q35.2q35.3; 
6q12q16.3 
a, mosaic/subclonal regions are underlined 
PT, posttransplant; IC, immunocompetent; mBL, molecular Burkitt lymphoma; M, male; ID, immunodeficient; IC, immunocompetent; CNI, 
calcineurin inhibitor; AM, antimetabolite; CS, low dose corticosteroids; TX, transplantation; PTLD, posttransplant lymphoproliferative disorder; EBV, 
Epstein-Barr virus; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; CT, chemotherapy; R, rituximab; CR, complete remission; 
PD, progressive disease; A, alive; D/du, dead, disease unrelated; D/dr, dead, disease related; NM, no mitosis; ND, not done; NF, not informative 
 
 
Legend to the Figure 
Figure 1. Genomic and transcriptomic data on PT-mBL. (A) Partial karyotype of case 5 (c5) and case 6 
(c6) showing chromosome 11 abnormalities and FISH images of both derivative chromosomes painted 
with WCP11 (green) and WCP8 (red) (case 5), and WCP18 (red) (case 6). The aberrations were 
eventually described as der(11)(11pter->11q23.3::11q23.3->11q13::8q22q24.3) and 
der(11)t(11;18)(q23.3;q12), respectively.  Note  (inverted) duplication of 11q13q23.3 in case 5 and a 
normal appearance of  this region in case 6. (B) Chromosomal view of chromosome 11q23q24 and 
imbalances identified by aCGH analysis in cases 5-7. Gained regions are highlighted in red-scale 
(increased intensity reflects an increased amplification level), while lost regions are marked in green. Note 
a variable level of 11q23.3 gain, a common loss of 11q24qter and the defined MLR (~4 Mb) and MLR 
(~13.5 MB). (C) Examples of interphase FISH analysis performed in case 5 (a) and case 6 (b, c). The 
applied probes include the 11q-MGR/MLR FISH assay (a) (b), and two probes from the duplicated (RP11-
284O21-SpectrumOrange) and amplified (RP11-784K23-SpectrumGreen; Supplementary Figure 2)  area 
in case 6 (c). Note the duplicated and amplified red/11q23.3 signal in (a) and (c), respectively, and loss of 
the green/11q24 signal in both cases. In (c), note two red and five green signals in the cluster, illustrating 
various levels of gain within MGR.  (D) Hierarchical clustering of mBL cases using the dysregulated genes 
located in the MGR and MLR. (E) Interaction network found by IPA involving genes targeted by the 11q-
gain/loss aberration (bold edges). Solid and interrupted lines represent direct and indirect interactions, 
respectively. Notably, most of the interactions in this network are direct protein-protein interactions. The 
molecules with blue and green edges are encoded by MGR- and MLR-associated genes, respectively.  
The data obtained by comparison of cases 5-7 (PT-mBL with the 11q-gain/loss pattern) (11q+/-) and 
cases 1-4 (PT-MYC-translocation-positive mBL) (t(MYC) were overlaid in this network. Molecules which 
are down- and upregulated in cases with 11q+/- when compared to cases with t(MYC) are filled in green 
and red, respectively. 
  
 
Supplementary information 
Supplementary Methods 
Cytogenetics and FISH 
G-banding chromosomal analysis and fluorescence in situ hybridization (FISH) followed routine 
methods. DNA probes, Bacterial Artificial Clones (BAC), applied for FISH were selected from 
www.Oct29012.archive.ensembl.org (Supplementary Figure 2). The probes were labeled with 
SpectrumOrange- and SpectrumGreen-d-UTP (Abbott Molecular, Ottigne, Belgium) using random 
priming. FISH images were acquired with a fluorescence microscope equipped with an Axiophot 2 
camera (Carl Zeiss Microscopy, Jena, Germany) and a MetaSystems ISIS imaging system 
(MetaSystems, Altlussheim, Germany). In each experiment up to 8 abnormal metaphases and/or 200 
interphase cells were evaluated. 
 
High resolution array Comparative Genome Hybridization (aCGH) 
Total genomic DNA was isolated from fresh frozen lymphoma samples using standard procedures. 
Genomic profiling, following the manufacturer’s protocols, was performed using the Affymetrix 
Cytogenetic array 2.7M (www.affymetrix.com). The initial data analysis was performed with the 
software “Chromosome Analysis Suit” (CHAS) and subsequent analysis (segmentation and aberration 
heatmap) were performed using the software “ArrayStudio” (www.omicsoft.com). Array CGH data are 
available at GEO (http://www.ncbi.nlm.nih.gov/projects/geo/query/acc.cgi?acc=GSE64086). 
 
Gene Expression profiling and pathway analysis 
Total RNA extraction was performed using TRIzol LS Reagent (Life Technologies Europe B.V., Gent, 
Belgium). The HG-U133 Plus 2.0  Affymetrix platform (www.affymetrix.com) was used and the raw 
data (CEL files) were normalized using the GeneChip-Robust Multiarray Averaging (GC-RMA) 
algorithm. Hierarchical clustering was applied to detect relationship in the data and to identify outliers. 
To find differentially expressed genes, the General Linear Model (GLM)  module of ArrayStudio was 
used for inference analysis. (www.omicsoft.com). Gene expression data are available at GEO 
(http://www.ncbi.nlm.nih.gov/projects/geo/query/acc.cgi?acc=GSE64086). 
The cases were classified using two molecular gene signatures of BL described by Hummel et al. 
20061 and Dave at al. 2006.2 As a control group, we selected 29 previously studied cases of DLBCL 
which were analyzed with the same Affymetrix platform.3 To group the cases using hierarchical 
clustering, we used the Ward and Manhattan methods for the linkage and distance, respectively. The 
clustering of the probes was done using complete link and Pearson’s correlation (see details:  
http://www.arrayserver.com/wiki/index.php?title=HierarchicalClustering). 
To identify 11q genes dysregulated in ID-BL with 11q-gain/loss pattern (11q+/-),  we performed 
inference analysis comparing three cases with 11q+/- versus four cases of MYC-translocation positive 
BL (t(MYC)). To find significant enriched pathways and biological functions in ID-BL with 11q+/-, we 
uploaded the result of the inference analyses into the “Ingenuity Pathway Analysis” application (IPA, 
www.ingenuity.com). From the three confidence levels provided by the system, we used 
“Experimentally observed” and “Highly predicted” data. For details see:  
http://ingenuity.force.com/ipa/articles/Tutorial/Tutorials.  
 
Statistical analysis 
Association between categorical variables was tested by the Fisher’s exact test. P-value <0.005 was 
considered statistically significant. 
 
Immunohistochemistry and chromogenic in situ hybridization 
Immunohistochemical stainings were performed on paraffin-embedded sections. All antisera were 
ready to use antibodies purchased from DAKO (DAKO, Carpinteria, USA) except for C-MYC (Y69, 
Epitomics, Abcam, Burlingame, CA, USA) and stained in automated fashion according to the 
manufacturer's recommendations. IHC results were visualized using the OptiView DAB IHC Detection 
Kit (Ventana, Oro Valley, Tucson, Arizona). Image acquisition was done through a Leica microscope 
at 200x and 100x magnification. Images were assembled using Adobe Photoshop CS5. 
Chromogenic EBER (EBV-encoded RNA) in situ hybridization is considered the standard for diagnosis 
of EBV-infection and was performed using a 30-mer digoxigenin-labeled oligonucleotide probe 
(Research Genetics, Huntsville, AL), according to manufacturer’s instructions. A control poly-A probe 
(Ventana Roche, Arizona USA) was used to check for RNA integrity and a proven EBV-driven 
lymphoma was used as a positive control.  
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 Supplementary Figure S1. Validation of the molecular features of 11 studied BL cases. 
 Hierarchical clustering using the BL signatures from Hummel et al. 20061 (A) and Dave et al.2 (B). All  
cases clustered together and were separated from 19 IC-DLBCL and 10  PT-DLBCL.3  These data 
were collected from our microarray experiment  in which  we used the HG-U133 Plus 2.0  Affymetrix 
platform. In this platform the gene annotation is based on the genome build Hg19. 
  
  
Supplementary Figure S2. Design of the 11q-MGR/MLR FISH assay. (A) View of chromosome 11 
with the indicated 11q23.3qter region; (B) 11q imbalances detected by aCGH in case 6, which showed  
the smallest  region of gain (~4 Mb); (C) Selected bacterial artificial chromosome (BAC) clones 
(www.Oct2012.archive.ensembl.org) and their genomic localization. Note that the assay  comprises 
three MGR-related BAC clones (labeled with SpectrumOrange-d-UTP, shown in red-scale) 
representing three differentially gained areas in case 6 and two clones spanning FLI1 (labeled with 
SpectrumGreen-d-UTP, shown in green), the gene targeted by biallelic deletion on one case reported 
by Salaverria et al.4  
 
 
  
  
Supplementary Figure S3. Expression value of selected genes. Normalized  signal values of array 
probes covering USP2, ETS1, PAFAH1B2, FLI1 and MYC. The p-value and the “corrected-for- 
multiple-testing” p-value (FDR) are provided  for the individual probes. 
 
  
  
Supplementary Figure S4. Morphology and immunophenotype of ID-mBL. Images in the top and 
bottom rows represent MYC-translocation-positive case 4 and case 5 with the 11q-gain/loss pattern, 
respectively.  (A) and (G), hematoxilin&eosin staining. In the remaining images, examples of 
immunohistochemistry for CD20 (B and H), CD10 (C and I), BCL2 (D and J), MYC (E and K) and Ki67 
(F and L).  The images were taken at 200x and then scaled. 
 
Supplemental Table S1. Differentially expressed genes in MGR (red) and MLR (green).
probe set id Gene Symbol Gene Title
11q+/- vs t[MYC] 
FoldChange
 11q+/- vs t[MYC] 
PValue Chromosome Start End Chromosomal band
224777_s_at PAFAH1B2 platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (30kDa) 1,5121 7,88E-05 chr11 117015043 117041759 chr11q23
202038_at UBE4A ubiquitination factor E4A 2,1626 0,0335 chr11 118230358 118269922 chr11q23.3
208745_at ATP5L ATP synthase, H+ transporting, mitochondrial Fo complex, subunit G 1,8159 0,0432 chr11 118272103 118280562 chr11q23.3
208746_x_at ATP5L ATP synthase, H+ transporting, mitochondrial Fo complex, subunit G 1,5583 0,0282 chr11 118272320 118279908 chr11q23.3
210453_x_at ATP5L ATP synthase, H+ transporting, mitochondrial Fo complex, subunit G 1,5499 0,0342 chr11 118272321 118279914 chr11q23.3
207573_x_at ATP5L ATP synthase, H+ transporting, mitochondrial Fo complex, subunit G 1,5705 0,0358 chr11 118272330 118279910 chr11q23.3
218483_s_at IFT46 intraflagellar transport 46 homolog (Chlamydomonas) 2,3249 0,0091 chr11 118415260 118436714 chr11q23.3
201176_s_at ARCN1 archain 1 2,7523 0,0114 chr11 118443147 118473613 chr11q23.3
225549_at DDX6 DEAD (Asp-Glu-Ala-Asp) box helicase 6 1,3804 0,0222 chr11 118500744 118620182 chr11q23.3
227208_at CCDC84 coiled-coil domain containing 84 2,6342 0,0394 chr11 118883892 118889035 chr11q23.3
200091_s_at RPS25 ribosomal protein S25 1,3548 0,0359 chr11 118886429 118889326 chr11q23.3
203292_s_at VPS11 vacuolar protein sorting 11 homolog (S. cerevisiae) 2,2357 0,0177 chr11 118938492 118952675 chr11q23
213344_s_at H2AFX H2A histone family, member X 1,8155 0,0209 chr11 118964583 118965076 chr11q23.3
205436_s_at H2AFX H2A histone family, member X 2,0447 0,0427 chr11 118964586 118966177 chr11q23.3
204757_s_at C2CD2L C2CD2-like 1,71 0,0475 chr11 118978783 118989043 chr11q23.3
206495_s_at HINFP histone H4 transcription factor 3,211 0,0171 chr11 118997642 119005764 chr11q23.3
1553695_a_at NLRX1 NLR family member X1 2,2767 0,021 chr11 119039439 119054725 chr11q23.3
219680_at NLRX1 NLR family member X1 2,2785 0,0016 chr11 119045428 119054723 chr11q23.3
229010_at CBL Cbl proto-oncogene, E3 ubiquitin protein ligase 2,6837 0,0246 chr11 119171132 119172744 chr11q23.3
225231_at CBL Cbl proto-oncogene, E3 ubiquitin protein ligase 2,0956 0,0272 chr11 119175481 119178857 chr11q23.3
225234_at CBL Cbl proto-oncogene, E3 ubiquitin protein ligase 1,9879 0,0279 chr11 119175481 119178857 chr11q23.3
229337_at USP2 ubiquitin specific peptidase 2 25,2497 0,0118 chr11 119225924 119226401 chr11q23.3
207211_at USP2 ubiquitin specific peptidase 2 1,372 0,0399 chr11 119227511 119234629 chr11q23.3
207213_s_at USP2 ubiquitin specific peptidase 2 30,6986 0,0144 chr11 119227511 119234629 chr11q23.3
204327_s_at ZNF202 zinc finger protein 202 -2,0264 0,0086 chr11 123594634 123612325 chr11q23.3
204329_s_at ZNF202 zinc finger protein 202 -1,7887 0,034 chr11 123594634 123612325 chr11q23.3
225819_at TBRG1 transforming growth factor beta regulator 1 -1,6264 0,0219 chr11 124492773 124502634 chr11q24.2
230320_at TBRG1 transforming growth factor beta regulator 1 -1,4489 0,0304 chr11 124504861 124505294 chr11q24.2
235654_at TMEM218 transmembrane protein 218 -1,6734 0,0319 chr11 124965539 124966001 chr11q24.2
226073_at TMEM218 transmembrane protein 218 -1,6272 0,024 chr11 124966576 124981604 chr11q24.2
208289_s_at EI24 etoposide induced 2.4 mRNA -1,6532 0,0395 chr11 125439411 125454575 chr11q24
216396_s_at EI24 etoposide induced 2.4 mRNA -1,7454 0,0167 chr11 125452532 125454124 chr11q24
202223_at STT3A STT3, subunit of the oligosaccharyltransferase complex, homolog A (S. cerevisiae) -1,9276 0,0081 chr11 125462741 125490953 chr11q23.3
221277_s_at PUS3 pseudouridylate synthase 3 -1,9179 0,004 chr11 125763379 125766209 chr11q24.2
225398_at RPUSD4 RNA pseudouridylate synthase domain containing 4 -2,1666 0,0062 chr11 126071990 126081531 chr11q24.2
223386_at FAM118B family with sequence similarity 118, member B -1,5259 0,0477 chr11 126081698 126132460 chr11q24.2
223128_at FOXRED1 FAD-dependent oxidoreductase domain containing 1 -1,8328 0,0025 chr11 126139054 126148026 chr11q24.2
1552804_a_at TIRAP toll-interleukin 1 receptor (TIR) domain containing adaptor protein -1,4053 0,0153 chr11 126153001 126163130 chr11q24.2
218774_at DCPS decapping enzyme, scavenger -2,0301 0,0227 chr11 126173969 126215644 chr11q24.2
224833_at ETS1 v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) -1,402 0,0027 chr11 128328659 128332010 chr11q23.3
1555355_a_at ETS1 v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) -1,3274 0,0412 chr11 128331389 128392160 chr11q23.3
214447_at ETS1 v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) -1,3826 0,0064 chr11 128332071 128392248 chr11q23.3
214875_x_at APLP2 amyloid beta (A4) precursor-like protein 2 -1,6967 0,049 chr11 129979330 130014283 chr11q24
202005_at ST14 suppression of tumorigenicity 14 (colon carcinoma) -1,9629 0,0261 chr11 130029839 130080256 chr11q24-q25
216905_s_at ST14 suppression of tumorigenicity 14 (colon carcinoma) -2,0863 0,0067 chr11 130058086 130080256 chr11q24-q25
226148_at ZBTB44 zinc finger and BTB domain containing 44 -1,8138 0,0349 chr11 130100253 130131329 chr11q24.3
220243_at ZBTB44 zinc finger and BTB domain containing 44 -2,3587 0,0376 chr11 130108974 130184321 chr11q24.3
202358_s_at SNX19 sorting nexin 19 -1,3925 0,0414 chr11 130745773 130786362 chr11q25
202359_s_at SNX19 sorting nexin 19 -1,5302 0,048 chr11 130745774 130786362 chr11q25
1554986_a_at SNX19 sorting nexin 19 -1,4202 0,0304 chr11 130775552 130786344 chr11q25
212789_at NCAPD3 non-SMC condensin II complex, subunit D3 -1,6052 0,0363 chr11 134022339 134093868 chr11q25
221669_s_at ACAD8 acyl-CoA dehydrogenase family, member 8 -1,3771 0,0254 chr11 134123464 134135555 chr11q25
